Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at A
ABP-671 effective at lowering serum uric acid, the cause of gout JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today that it will present final dated data from its Phase 2a clinical trial of its s...